Gottlieb Lab

The Gottlieb Laboratory, led by Roberta A. Gottlieb, MD, is studying the molecular mechanisms regulating mitochondria in the heart’s response to ischemic injury. The Gottlieb Lab is also exploring the metabolic output of mitochondria (ATP, NADH/NAD+, AcCoA, etc.) that affect chromatin structure and gene expression including miRNAs. The goal of the Gottlieb Laboratory is to identify druggable pathways that can mitigate postinfarction heart failure. In earlier work, the Gottlieb Lab found that autophagy and mitophagy play a central role in the heart's tolerance to ischemic injury. Autophagy, or intracellular recycling, is diminished in aged animals or in those that develop diet-induced obesity and glucose intolerance. Our lab uses cells, mice, large animals and human tissue to study autophagy, mitophagy and mitochondrial biogenesis in order to restore its beneficial activity in the diseased heart. The Gottlieb Lab's focus on mitochondria has led to multiple collaborations within and outside of Cedars-Sinai, including studying many diseases in which mitochondria play an important role, such as cancer, autoimmune disease, liver disease and more.

Gottlieb Lab members contribute their expertise to the Cedars-Sinai Mitochondria, Metabolism and Cardiac Phenotyping Core.

The Gottlieb Laboratory is affiliated with the Cedars-Sinai Smidt Heart Institute, Barbra Streisand Women's Heart Center, Department of Medicine and Department of Biomedical Sciences.